Biothera Pharmaceuticals to Present at The Canaccord Genuity Growth Conference

EAGAN, Minn.--()--Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:30 a.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera Pharmaceuticals and a business update.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymphocytic leukemia. The Company is currently planning phase 2 clinical trials to evaluate Imprime PGG in combination with checkpoint inhibitors in NSCLC, triple negative breast cancer, melanoma and squamous cell carcinoma of the head and neck.

Contacts

Biothera
David Walsh, 651-256-4606
SVP Communications
dwalsh@biothera.com

Release Summary

Biothera Pharmaceuticals CEO Barry Labinger will provide an overview of the Company and a business update at the Canaccord Genuity Growth Conference at 11:30 am ET on Wed., Aug 10 in Boston.

Contacts

Biothera
David Walsh, 651-256-4606
SVP Communications
dwalsh@biothera.com